Once placed, the NuvaRingĂ‚Â® is intended to remain in place for how many weeks before being removed?

Question:

	1. 1 week
	2. 2 weeks
	3. 3 weeks
	4. 4 weeks
	5. 5 weeks

Answer:

The correct answer for the question "Once placed, the NuvaRingĂ‚Â® is intended to remain in place for how many weeks before being removed?" is:

3. 3 weeks

Explanation
1. 1 week is too short of a course for NuvaRingĂ‚Â® placement. The device should remain in place for 3 weeks prior to removal. [The NuvaRingĂ‚Â® is intended to remain in place for 3 weeks, during which it releases about 0.015 mg/day of ethinyl estradiol (EE) and 0.120 mg/day of etonogestrel.]
2. A 2 week course does not mimic physiologic hormonal variations. NuvaRingĂ‚Â® should thus remain in place for 3 weeks before being removed. [The NuvaRingĂ‚Â® is intended to remain in place for 3 weeks, during which it releases about 0.015 mg/day of ethinyl estradiol (EE) and 0.120 mg/day of etonogestrel.]
3. Once placed, the NuvaRingĂ‚Â® is intended to remain in place for 3 weeks before it is to be removed. [The NuvaRingĂ‚Â® is intended to remain in place for 3 weeks, during which it releases about 0.015 mg/day of ethinyl estradiol (EE) and 0.120 mg/day of etonogestrel.]
4. 4 weeks of NuvaRingĂ‚Â® usage before removal is too long. The device is advised to be left in place for 3 weeks prior to removal. [The NuvaRingĂ‚Â® is intended to remain in place for 3 weeks, during which it releases about 0.015 mg/day of ethinyl estradiol (EE) and 0.120 mg/day of etonogestrel.]
5. To most accurately mimic a physiologic menstrual cycle, a NuvaRingĂ‚Â® should be left in place for 3 weeks before being removed. Leaving the device in place for 5 weeks would be too long of an exposure. [The NuvaRingĂ‚Â® is intended to remain in place for 3 weeks, during which it releases about 0.015 mg/day of ethinyl estradiol (EE) and 0.120 mg/day of etonogestrel.]

From the manuscript:
Inadvertent intravesicular placement of a vaginal contraceptive ring: a case report and review of literature
Radiology Case. 2014 Dec; 8(12):22-28

This article belongs to the section.

From the manuscript

Inadvertent intravesicular placement of a vaginal contraceptive ring: a case report and review of literature

Free full text article: Inadvertent intravesicular placement of a vaginal contraceptive ring: a case report and review of literature

Abstract
The NuvaRing® is a deformable, ring-shaped hormonal contraceptive device which is typically vaginally self-inserted by the patient. While there are several potential side effects of usage, essentially all of them result from hormone delivery. Complications from incorrect placement are rare. We present the case of a 31 year old female who presented to our emergency department after being unable to retrieve a NuvaRing® for its scheduled removal. CT scan showed a hypodense intravesicular NuvaRing® which the patient had inadvertently placed transurethrally 3 weeks prior. Cystoscopy was performed and retrieval using a 3-pronged grasper was eventually successful after several failed attempts with an alligator grasper. Our purpose in presenting this case is to introduce the reader to a rare complication of incorrect NuvaRing® placement, explain how this complication may occur as a result of NuvaRing® construction/functionality, describe how alternative cystoscopic instruments may aid in cystoscopic retrieval, and review the 3 other case reports of intravesicular NuvaRing® placement to discuss the utility of various imaging modalities when clinical suspicion of the complication is high.

References

1. Wieder DR, Pattimakiel L. Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing®). Int J Womens Health 2010 Nov 12; 2:401-409